Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is when you know you have a great company
This is when you know you have a great company
Slow but steady! up over almost 200%. Hanging on to my shares till $25
They purchased $3.5 million in shares at $1 each. That shows a lot of faith in the company and will provide the company with a ton of cash.
I wonder if they have to buy those at market? I cannot remember ....
The company just did a private placement. Management bought 3.5 million shares at $1 per share. Pretty impressive. They know the company best and just invested at $1.
Then the treatment from AURX is going to be sought after. They take platelets , run through AURX process, then coat wound with mixture, bringing about much quicker healing process for the body. All done in one doctor visit. The need is really high because of diabetic patient rise. Icing on the cake, government is paying for this treatment via Medicare/Medicaid.
There are no shares available. This could squeeze to $40 with pressure.
AURX seems to be holding its gains in an overall terrible market. Someone is bidding 21K to buy at 1.06. Would love to see it start a second leg higher.
Was there news yesterday that I didn't see or is the stock just finally being discovered?
Aurix now has CMS coverage! https://www.aurixsystems.com/coverage/
WOW! Look at this advanced wound care system. https://www.aurixsystems.com/
Wow, I have never seen a float locked like this, this is going to fricking ROCKET
Hard to get shares, I got a few, THE FLOAT IS LOCKED. The AURX wound treatment is ground breaking
Looks like today is the day it will explode. AURX is up over 1000% today.
Took awhile.....lol....what does it say?
z
Interesting product on AURX.......Being Current will help......
z
$AURX Tier_Change: Pink No Information to Pink Current
OTCM Link
https://www.otcmarkets.com/stock/AURX/disclosure
Lots of buzz here, lets keep that momentum and see copper this week.
I really hope so.
with all the insider buying and the news, it seems the insiders have a plan.
any back up plan here
I hope AURX will find a solution not to cease operations. They have a good product and FDA approved.
It doesn't look good, but i don't know what will be said on the call
i cant pull up the press release, can someone post it
AURX clear manipulation today, but I'm banking on those form 4s that were all filed recently on the same day.
Such a clear clue here
$AURX multiple form 4s out recently, insiders own 70%?? Plus amazing DD behind this one. Only 23M O/S
$AURX Next stop easily 20 cents. After that, who knows
$AURX 100% ON LOW VOLUME??? What does that tell you? This stock has LEVERAGE.......... ok..... ok....... what does THAT mean?
You put up a LITTLE dough....... and you make ALOT OF DOUGH in return....
Multiple form 4s, insiders bought MILLIONS of dollars worth of $AURX stock
I'm not saying anymore
$AURX is about to blow the roof off IMO....... too many filings
AURX traders are super slow on the OTC, no surprise here
EXACTLY!!! LOL. Insiders own 70% of the shares, they dont want to share lol. NO ONE knows about this stock. It fell from $2 to $1 on only 100 shares!!! $200 bucks??!! And fell from $1 to 5 cents on nothing. AURX is just as THIN on the way up.
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
Up 100% friday and no following here? Something may be brewing
No one is in her yet. NICE TO meet you my friend!!
$AURX .20?! ONLY 1.8 MILLION FLOAT!NOT-A-MISPRINT WHY DO INSIDERS OWN OVER 70% OF SHARES? UNKNOWN to 99.99999% of traders, moves on a air on a power scale less than a whisper #BIOTECH GEM. 6 INSIDERS just ADDED SHARES per the 7 January 3rd filings and I'm the only trader that knows (I guess)!!!!? 6 Form 4 filing silently out, NO ONE NOTICED. WHY?????? Last time I alerted it at .05 it ran to .575 in 5 days. Nothing has changed since then...oh wait 1 thing has changed, INSIDERS BOUGHT MORE SHARESSSSSS!
David Jorden: Peter Clausen:
Eric Winzer: Scott Pittman: Lawrence Atinsky: Paul Mintz: ALL 6 just LOADED!! Exercise price ...wait for it... 40 CENTS!!! Shhhhh.
AURX is THE FIRST platelet & plasma therapy system TO BE CLEARED by the FDA for the management of ulcers & wounds of all types & all severities? https://t.co/yPfwfHL1V8????
Private placement at 30 cents and traders are ignoring this at 20 cents?! I'm compelled to ask myself do I have super vision or is everyone else using a Navigation system created by the 3 blind mice? What more can i say? I'm trying to keep it do simple a 4 year old could understand it.
$AURX why did SHEEDY CHARLES E purchase 5.2 million shares at 22 cents (that's over $1.1 million folks) to add to the 3 million he already owned? He graduated from Harvard Business school so trust me he has a LITTLE smarts, maybe a tiny bit of intelligence.
https://t.co/vI58wsa8W8
why did Boyalife Investment Fund I, Inc just purchase 3.1 million shares at .22 (DO THE MATH) #biotech gem #stocks #stockmarket #stocktrading #BTC
The only thing common about common sense is that it's UNCOMMON.
https://www.otcmarkets.com/stock/AURX/disclosure
Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1998 and is based in Gaithersburg, Maryland.
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
$AURX Who else is in this? I just bought 30k shares past few days?
REMEMBER THAT AURX ONLY HAS A ....WAIT FOR IT.... 1.8 MILLION FLOAT!!!!!! Read that again.
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
Yes that's amazing without a doubt.
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
IF YOU DIDNT KNOW.
$AURX THE FIRST platelet & plasma therapy system 2 B cleared by the FDA for the managment of ulcers & wounds of all types & all severities? https://t.co/yPfwfHL1V8????
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
$AURX new MM NORT on L2 no 1 has ever seen this MM on any penny stock before. Why is he here??! shhhhhhhhhh
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
(OTCPK:AURX) is looking for acquisitions. Nuo Therapeutics may also use a portion of the net proceeds for the acquisition of, or investment in, technologies, solutions or businesses
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
AURX we believe the storm has passed the fundamentals have bottomed. In fact, we believe the tide has already turned in the company's favor, despite the stock price.
They currently have $600k Cash ON HAND , the valuation is WAY too attractive to ignore.
AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX AURX
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
154
|
Created
|
02/13/18
|
Type
|
Free
|
Moderators |
Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies within the emerging opportunities of a changing healthcare landscape.
Through bold leadership, better clinical solutions, and products that add true value to a patient’s health, we aim to offer more effective and efficient therapies for healing.
Nuo Therapeutics’ flagship product, Aurix™, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. It is the only therapy of its kind that is FDA-cleared for use on ulcers and wounds of all types.
Dr. Clausen joined Nuo Therapeutics in September 2008 and has more than 20 years of experience in the biotechnology industry. Prior to joining Nuo Therapeutics, Dr. Clausen was a founding member and Vice President of Research and Development at Marligen Bioscience, where he developed and commercialized innovative genomic and protein analysis products for the life sciences market. Dr. Clausen was the Manager of New Purification Technologies at Life Technologies and the Invitrogen Corporation. He also has significant experience within the commercial biotechnology industry developing peptide and small molecule therapeutics for application in the areas of inflammatory mediated disease and stem cell transplantation. He completed his post-doctoral training at the Laboratory of Molecular Oncology at the National Cancer Institute where his research efforts focused in the areas of oncology, hematopoiesis, and gene therapy. Dr. Clausen earned his PhD in Biochemistry from Rush University in Chicago and a Bachelor of Science degree in Biochemistry from Beloit College.
David E. Jorden has been Chief Executive Officer and Chief Financial Officer of the Company effective July 1, 2016 after serving as Acting CEO since January 8, 2016 and Acting CFO since May 2015. Mr. Jorden also serves as Acting Secretary of the Company, and has served on the Board of Directors since October 2008 and was Executive Chairman from February 2012 to May 2015. From 2003 to 2008, he was with Morgan Stanley’s Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a MBA from Northwestern University’s Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr.Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA) where he has held the position of Acting Chief Financial Officer since August 2012. He is also on the board of a private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs). Mr. Jorden brings his experience and expertise in the areas of capital raising, investor relations, financial management and analysis, and business strategy to the Board and the Company.
Board of Directors
David E. Jorden has been Chief Executive Officer and Chief Financial Officer of the Company effective July 1, 2016 after serving as Acting CEO since January 8, 2016 and Acting CFO since May 2015. Mr. Jorden also serves as Acting Secretary of the Company, and has served on the Board of Directors since October 2008 and was Executive Chairman from February 2012 to May 2015. From 2003 to 2008, he was with Morgan Stanley’s Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a MBA from Northwestern University’s Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr.Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA) where he has held the position of Acting Chief Financial Officer since August 2012. He is also on the board of a private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs). Mr. Jorden brings his experience and expertise in the areas of capital raising, investor relations, financial management and analysis, and business strategy to the Board and the Company.
Paul D. Mintz, MD was elected to the Nuo Therapeutics, Inc. Board of Directors, effective April 7, 2017. Dr. Mintz is currently the Senior Vice President and Chief Medical Officer of Verax Biomedical. Prior to joining Verax Biomedical in early 2016, Dr. Mintz served as Director, Division of Hematology Clinical Review, Office of Blood Research and Review, Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration. Prior to that, for more than 30 years, Dr. Mintz was a member of the faculty of the University of Virginia School of Medicine, where he was a tenured Professor of Pathology and Internal Medicine. He also served as Vice-Chair of Pathology and Chief of the Division of Clinical Pathology, and as Medical Director of the Clinical Laboratories and Transfusion Medicine Services at the University of Virginia Health System. In addition, Dr. Mintz served as Co-Medical Director of Virginia Blood Services. Dr. Mintz is a former President of the American Association of Blood Banks (AABB), served on the AABB’s Board of Directors for nine years, and was a member of and chaired numerous AABB committees. Dr. Mintz is a recipient of the AABB’s John Elliott Memorial Award. He has also served as a member of the Board of Trustees of the National Blood Foundation. Dr. Mintz is the recipient of a Transfusion Medicine Academic Award from the National Heart, Lung and Blood Institute, and was an inaugural inductee into the National Blood Foundation Hall of Fame. He also served as a member of the Medicare Coverage Advisory Committee of the Centers for Medicare and Medicaid Services (CMS). Dr. Mintz is author or co-author of more than 100 articles and editorials spanning clinical practice, blood safety and the evaluation of new transfusion medicine technologies, and has designed and served as principal investigator for numerous clinical trials. He is the sole editor of all three editions of Transfusion Therapy: Clinical Principles and Practice (AABB Press) and has served on several journal editorial boards. Dr. Mintz earned his BA in Philosophy from the University of Rochester and received his MD with honors from the University of Rochester School of Medicine. Dr. Mintz brings considerable knowledge of platelet biology and transfusion medicine, along with senior regulatory and reimbursement experience to Nuo Therapeutics, and will be enormously valuable as the company strives to advance the Aurix System toward broader commercialization in the large and growing chronic wound care market.
C. Eric Winzer has served as Director since January 30, 2009. Mr. Winzer has over 30 years of experience in addressing diverse financial issues including raising capital, financial reporting, investor relations, banking, taxation, mergers and acquisitions, financial planning and analysis, and accounting operations. Mr. Winzer has been the Chief Financial Officer at Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company, since May 2015. From June 2009 to April 2015 Mr. Winzer served as the Principal Accounting Officer, Senior Vice President of Finance, and Chief Financial Officer for OpGen Inc. (OPGN), a precision medicine company that went public in May 2015. Before his tenure with OpGen Inc., Mr. Winzer held multiple executive positions at Avalon Pharmaceuticals, Inc. (AVRX), a NASDAQ listed biotechnology company, including serving as its Chief Financial Officer and Executive Vice President, Principal Accounting Officer, and Secretary. Before joining Avalon Pharmaceuticals, Mr. Winzer held numerous senior financial positions over twenty years at Life Technologies Corporation (LIFE) (now part of Thermo Fisher Scientific (TMO)) and its predecessor companies, Invitrogen (IVGN) and Life Technologies, Inc. (LTEK). From 1980 to 1986, Mr. Winzer held various financial positions at Genex Corporation. Mr. Winzer has been an Independent Director at Nuo Therapeutics (f/k/a Cytomedix, Inc.) since January 30, 2009. Mr. Winzer holds a B.A. in Economics and Business Administration from Western Maryland College (now, McDaniel College) and an M.B.A. from Mount Saint Mary's University. Mr. Winzer was chosen to serve as a director of the Company in part because of his executive experience in the life sciences industry and his substantial financial knowledge and expertise.
Lawrence S. Atinsky has served as a director since May 5, 2016. Mr. Atinsky is a Partner at Deerfield Management Company, LP (“Deerfield Management”), a healthcare investment firm focused on advancing healthcare through investment, information and philanthropy. He primarily focuses on the firm’s structured transactions and private equity investments. Prior to joining Deerfield Management, Mr. Atinsky was a partner of Ascent Biomedical Ventures, a healthcare focused private equity firm investing in early-stage biomedical and medical device companies. He has over 18 years of experience investing in healthcare companies and currently serves on the Board of FluoroPharma Medical, Inc. Mr. Atinsky earned a J.D. from New York University School of Law and B.A. degrees in Political Science and Philosophy from the University of Wisconsin-Madison, cum laude. Deerfield Management’s affiliates are currently the sole holders of our Series A Preferred Stock and Mr. Atinsky serves as their designee to our Board of Directors under the Certificate of Designations for our Series A Preferred Stock.
Scott M. Pittman has served as a director since May 5, 2016. Mr. Pittman has over 30 years in Hospital Executive management. He is a Chief Operating & Business Development Officer for Buchanan General Hospital, a Registered Representative with Calton & Associates, and a Principal of Hospital CEO Associates. He has served as CEO Florida Hospital Zephyrhills, FL, in senior executive positions with Adventist Health Systems, and in various hospital executive positions in southern West Virginia. Mr. Pittman has developed several multimillion dollar hospital and program service expansions, and healthcare entity acquisitions and mergers, and has served on numerous state and regional health planning organizations. He is a Magna cum Laude graduate of Southwestern Adventist University with B.S. & B.A. Degrees in Business and Religion, and a Masters of Hospital Administration from Medical College of Virginia. Mr. Pittman was chosen to serve as a director of the Company in part because of his extensive experience as a hospital executive.
Aurix™ is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms to jumpstart the natural healing process.
Aurix is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (DFU, pressure, VLU, etc.) and all severities (partial thickness, full thickness, and complex wounds).
Aurix is effective at all stages of wound care for non-healing wounds, allowing providers more treatment flexibility across a broader range of patients.
Aurix™ is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms to jumpstart the natural healing process.
Aurix is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (DFU, pressure, VLU, etc.) and all severities (partial thickness, full thickness, and complex wounds).
Aurix is effective at all stages of wound care for non-healing wounds, allowing providers more treatment flexibility across a broader range of patients.
For more information about our company or our products, please contact or fill out the form on www.nuot.com/contact/
Corporate Offices
207A Perry Parkway, Suite 1
Gaithersburg, MD 20877
Nashville Office
618 Church St., Suite 305
Nashville, TN 37219
Phone
1.866.298.6633
Fax
1.240.499.2690
Email
info@nuot.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |